camrelizumab alone (n=228) vs. Standard of Care (SoC) (n=220)
randomized controlled trial
camrelizumab
camrelizumab 200 mg every 2 week. Dose reduction of camrelizumab was not permitted.
docetaxel or irinotecan
chemotherapy with docetaxel (75 mg/m2 every 3 weeks) or irinotecan (180 mg/m2 every 2 weeks) : docetaxel (19.5%) or irinotecan(80.5%)
mEC - 2nd line (L2)
Asian only
open label
43 hospitals in China
p3 /one sided and Interim analysis. Only OS at one sided level : 0.025 This study only involves one final analysis of the primary endpoint OS and the multiplicity issues will not be involved
Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy